Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICROGESTIN FE 1.5/30 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: ethinyl estradiol (estrogen) and norethindrone acetate (progestin) suppress gonadotropin (FSH, LH) release, preventing ovulation; increase cervical mucus viscosity, inhibiting sperm penetration; alter endometrial development, reducing implantation likelihood.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women >=15 years who have achieved menarche and are not pregnant or otherwise contraindicated,Treatment of heavy menstrual bleeding (off-label),Emergency contraception (off-label)
Prevention of pregnancy (FDA-approved)
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily for 28-day cycles (21 active tablets + 7 ferrous fumarate tablets).
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 6-8 hours (terminal); Ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; dosing interval suitable for once-daily administration.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: primarily metabolized via CYP3A4; undergoes first-pass metabolism in gut and liver. Norethindrone acetate: deacetylated to norethindrone, metabolized mainly via reduction and conjugation (glucuronidation, sulfation), partly by CYP3A4.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Norethindrone: 50-60% renal (as metabolites), 20-40% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal (as glucuronide/sulfate conjugates).
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: ~97% albumin and SHBG; Ethinyl estradiol: ~98% albumin (induces SHBG synthesis).
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: 2-5 L/kg (wide distribution, including breast tissue and adipose); Ethinyl estradiol: 2-4 L/kg (extensive distribution into reproductive tissues).
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Norethindrone: ~64% (oral, first-pass metabolism); Ethinyl estradiol: ~40-45% (oral, first-pass metabolism).
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). Not recommended in severe impairment (e GFR <30 m L/min/1.73 m²) due to limited data.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A (mild impairment), use with caution; no specific dose adjustment established, but may increase risk of adverse effects.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Approved for postmenarcheal adolescents. Dose same as adults: one tablet orally once daily for 28-day cycles. Not indicated for premenarcheal patients.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in women over 65 years due to lack of efficacy and safety data; increased risk of thromboembolic events and cardiovascular disease outweighs potential benefit.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (>=15 cigarettes/day). Women >=35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (venous thromboembolism, arterial thrombosis, stroke, MI),Carcinoma of breast/cervix,Hepatic disease (jaundice, tumors),Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid effects,Headache/migraine,Vaginal bleeding irregularities,Depression,Hereditary angioedema,Chloasma,Pregnancy loss
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders,History of DVT/PE,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Carcinoma of endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma/carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women >=35 years,Uncontrolled hypertension,Diabetes with vascular involvement,Major surgery with prolonged immobilization
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions. Grapefruit juice may increase estrogen levels but no specific restriction is required. Iron tablets should be taken on an empty stomach for best absorption, but can be taken with food if GI upset occurs.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FDA Pregnancy Category X. First trimester: No increased risk of major birth defects from inadvertent use, but post-fertilization effects are theoretical. Contraindicated in pregnancy due to estrogen component and progestin exposure. Second/third trimester: Irrelevant as drug is contraindicated; no fetal exposure studies. Use in pregnancy may cause fetal harm: possible congenital anomalies (limb defects, heart defects) and adverse outcomes (low birth weight, premature birth, neonatal withdrawal) with prolonged exposure.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of ethinyl estradiol and norethindrone acetate are excreted in breast milk (estimated ~0.1% of maternal dose). M/P ratio not established. No adverse effects on nursing infant or milk production reported with combined oral contraceptives; however, WHO recommends avoiding combined OCs during lactation until weaning or at least 6 months postpartum due to theoretical risk of estrogen affecting milk production. Use caution; consider progestin-only alternative.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy; no dose adjustment applicable. If pregnancy occurs, discontinue drug immediately. No pharmacokinetic data indicating need for dose changes in pregnancy because drug is not used during pregnancy.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
MICROGESTIN FE 1.5/30 contains norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg, plus ferrous fumarate (iron) tablets. The iron tablets are not part of the contraceptive regimen and should be taken only if iron deficiency is a concern. Because it is a combination oral contraceptive (COC), it has higher estrogen content compared to low-dose pills, which may increase the risk of thromboembolism. It is indicated for contraception and may also be used for menstrual disorders. The ring in the package is a placebo indicator; be aware that patients may confuse the iron tablets for active pills.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one active pill at the same time each day, followed by the brown iron tablets during the last 7 days of the pack.,If you miss a dose, follow the package instructions: take the missed pill as soon as remembered, and use backup contraception if more than one pill is missed.,Smoking increases the risk of serious cardiovascular side effects from birth control pills, especially if you are over 35.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, which often resolve within a few months.,This pill does not protect against HIV or other sexually transmitted infections.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICROGESTIN FE 1.5/30 vs AFIRMELLE, answered by our medical review team.
MICROGESTIN FE 1.5/30 is a Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol (estrogen) and norethindrone acetate (progestin) suppress gonadotropin (FSH, LH) release, preventing ovulation; increase cervical mucus viscosity, inhibiting sperm penetration; alter endometrial development, reducing implantation likelihood.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICROGESTIN FE 1.5/30 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICROGESTIN FE 1.5/30 is: One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily for 28-day cycles (21 active tablets + 7 ferrous fumarate tablets).. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICROGESTIN FE 1.5/30 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICROGESTIN FE 1.5/30 is classified as Category C. FDA Pregnancy Category X. First trimester: No increased risk of major birth defects from inadvertent use, but post-fertilization effects are theoretical. Contraindicated in pregnan. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.